menu toggle

Video: FreightWaves Supply Chain Update - Cell and gene therapy commercialization

By World Courier

Key considerations of cell and gene therapy cold chain logistics: redefining the supply chain

Cell and gene therapies are at the forefront of innovation and bring much hope for the future of medicine, they could transform how we treat and potentially cure certain diseases, so the stakes are really high. But they come with new considerations for therapy owners as they are brought to the market. The nature of these treatments and their use of living cells or genetic material create new intricacies and dependencies that disrupt the traditional commercialization process. For the first time, the patient is now part of the supply chain.

“When it comes to cell and gene therapies we are talking about an interconnected and personalized model which requires a higher degree of integration between specialized logistics partners, patient programs, and the health outcomes evidence which is required to drive physician adoption.”, Keegan Moore, Regional Sales Director

In an interview with FreightWaves, Keegan Moore, shares insights about cell and gene therapy commercialization and the shipping requirements therapy developers need to plan for in order to meet patient and provider expectations.

World Courier is the market-leading logistics platform developer for advanced therapies. We manage time-sensitive and temperature-critical shipments, supported by highly specialized and dedicated teams.

Our Logistics Platform has been managing critical shipments for advanced therapy developers since 2005. We annually deliver to over 2,000 clinical sites globally through a network of over 140 offices in more than 50 countries operating within a single quality system. This enables shipments of live cells across international and domestic boundaries while ensuring cell viability and transport security, even when an x-ray is not allowed.

We currently manage everything from donations through critical blood samples to the delivery of final therapies.

Find out more